Evidence map›Paper›PMID 38368261›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Escherichia coli-Induced cGLIS3-Mediated Stress Granules Activate the NF-κB Pathway to Promote Intrahepatic Cholangiocarcinoma Progression.

Feng-Ping Kang, Zhi-Wen Chen, Cheng-Yu Liao, Yong-Ding Wu, Ge Li, Cheng-Ke Xie, Hong-Yi Lin, Long Huang, Yi-Feng Tian, Zu-Wei Wang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Organoids and spheroids: advancedFrontiers in cell and developmental biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Feng-Ping KangShengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Zhi-Wen ChenShengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.ORCID 0000-0002-1770-6208
Cheng-Yu LiaoShengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Yong-Ding WuShengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Ge LiDepartment of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, 350001, China.
Cheng-Ke XieShengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Hong-Yi LinShengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Long HuangDepartment of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, 350001, China.
Yi-Feng TianShengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Zu-Wei WangShengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.ORCID 0000-0002-2568-9364
Shi ChenShengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.ORCID 0000-0002-8207-7479
Fujian Medical University · CNFujian Provincial Hospital · CN

Funding

Fujian Research and Training Grants for Young and Middle-aged Leaders in Healthcare 2021(60)Major Scientific Research Project of Young and Middle-aged people of Fujian Provincial Health Commission 2021ZQNZD001National Natural Science Foundation of China 82173250Natural Science Foundation of Fujian Province of China 2021J01365Special Funding Project of Fujian Provincial Department of Finance 2100201
6 · The paper itself

Abstract

Patients with concurrent intrahepatic cholangiocarcinoma (ICC) and hepatolithiasis generally have poor prognoses. Hepatolithiasis is once considered the primary cause of ICC, although recent insights indicate that bacteria in the occurrence of hepatolithiasis can promote the progression of ICC. By constructing in vitro and in vivo ICC models and patient-derived organoids (PDOs), it is shown that Escherichia coli induces the production of a novel RNA, circGLIS3 (cGLIS3), which promotes tumor growth. cGLIS3 binds to hnRNPA1 and G3BP1, resulting in the assembly of stress granules (SGs) and suppression of hnRNPA1 and G3BP1 ubiquitination. Consequently, the IKKα mRNA is blocked in SGs, decreasing the production of IKKα and activating the NF-κB pathway, which finally results in chemoresistance and produces metastatic phenotypes of ICC. This study shows that a combination of Icaritin (ICA) and gemcitabine plus cisplatin (GP) chemotherapy can be a promising treatment strategy for ICC.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaDisease ProgressionEscherichia coliNF-kappa BStress GranulesAnimalsDisease Models, AnimalDNA HelicasesGemcitabineHumansMicePoly-ADP-Ribose Binding ProteinsRNA HelicasesRNA Recognition Motif ProteinsSignal TransductionDNA HelicasesG3BP1 protein, humanGemcitabineNF-kappa BPoly-ADP-Ribose Binding ProteinsRNA HelicasesRNA Recognition Motif ProteinscircGLIS3Escherichia coliIcaritinintrahepatic cholangiocarcinomaNF‐κBstress granules

Identifiers

PMID38368261
PMCPMC11040339
OpenAlexW4392782740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.